“showed a trend”

Those who received chemotherapy also showed a trend for receiving tamoxifen (43.1% vs. 34.6%, P = 0.002).

The Wilcoxon signed rank test was not significant ( p =0.086), but showed a trend pointing into the same direction as the parametric mixed-effects model, which compares mean values ( p =0.002).

In contrast, the BP slope in the IH patients showed a trend towards a decrease with each hour (−0.3 mmHg/hr) during the first 24 hours, and this change was different from not only the same time period in controls (p=0.002, Figure 1 ), but also when compared to hours 25–44 in the IH patients (p=0.001).

Transplantation showed a trend toward improvement in intestinal tissue damage and a decrease in inflammatory cell infiltration (loss of epithelium: p=0.0022, crypt damage: p=0.0087, depletion of goblet cell: p=0.0433, histological score: p=0.0043) ( Fig. 3E ).

Phase III studies involving chemotherapy with or without bevacizumab presented during the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) showed a trend toward an overall survival benefit in patients treated with bevacizumab in addition to chemotherapy in the first line setting with HR = 0.64 P = 0.0022 in those with poor prognosis disease (ICON7).

In untreated multiple sclerosis patients, the myeloid cell subset showed a trend for decreased CD40 MFI ( P = 0.0024) ( Supplementary Fig. 10 ).

The mRNA and protein levels of IFN-γ showed a trend similar to that of TNF-α (DRG: day 8, P =0.00244, day 14, P =0.00029, SC: day 8, P =0.00049, day 14, P =0.00096, HIP: day 8, P =0.00424, day 14, P =0.00288, Fig. 1 c; DRG: day 8, P =0.053, day 14, P =0.0021, SC: day 8, P =0.016, day 14, P =0.0060, HIP: day 8, P =0.023, day 14, P =0.078, Fig. 1 e).

The adjusted OR ( a OR) (99% CI) to complete ≥12 years of schooling stratified by parental SES, when comparing the childhood obesity cohort with the comparison group, showed a trend towards lower OR in the higher level of SES: low parental SES=0.69 (0.50 to 0.95), p=0.0026; medium-low parental SES=0.59 (0.48 to 0.72), p<0.0001; medium-high parental SES=0.46 (0.35 to 0.60), p<0.0001; high parental SES=0.27 (0.14 to 0.54), p<0.0001.

Both patients with high nuclear and cytoplasmic ADAR1 expression showed a trend toward shorter survival after distant metastasis (nucleus ( p = 0.0026) and cytoplasm ( p < 0.001); Fig. 1 C).

Both male and female mice showed a trend towards higher alpha-diversity with SCFA treatment, with male mice reaching statistical significance at the taxonomic levels of order ( p = 0.0027), class ( p = 0.0027) and phylum ( p = 0.043) and female mice reaching significance at the genus ( p = 0.049) taxonomic level ( Figures 2A,C , p -values for all taxonomic levels in Table 1 ).

Meanwhile, patients in the ACDF group showed a trend of significantly higher BMI (ACDF/LAMP = 30.72/29.57, p = 0.0027), preoperative dyspnea (ACDF/LAMP = 7.24%/2.74%, p = 0.0004), and lower preoperative hematocrit (ACDF/LAMP = 40.79/41.86, p < 0.0001) compared with the LAMP group ( Table 1 ).

79.92±13.09 (MPTP + sham EA), p = 0.6208, Figure 7A,B ]; results from the Western blot analysis also showed a trend similar to that obtained with immunohistochemistry [0.9±0.03 (MPTP + EA + K252a) vs. 1.3±0.13 (MPTP + EA), p = 0.0029, 0.9±0.03 (MPTP + EA + K252a) vs. 1±0.058 (MPTP + sham EA), p = 0.3333, Figure 7C,D ].

In the RNA-Seq data, TET3 showed a trend for differential expression in the SGA placentas (DESeq: P = 0.0029; DESeq2: P = 0.00035).

Subjects with laboratory evidence of recent strep exposure (defined as either ASO or anti-DNase B antibody titers of equal to, or more than, the ULN value during pregnancy), showed a trend toward an association with asthma when compared with unexposed individuals (33.3% versus 11.1%, P = 0.003 considering Bonferroni correction). 4.

The Kaplan–Meier analysis showed a trend toward higher HF hospitalization ( P = 0.003) and a higher occurrence of an upgrade to BiVP ( P = 0.027) in the RVP group than in the LBBAP group ( Figure 3 ).

The alteration of hepatic TTR showed a trend contrary to that of hepatic RBP4, in that significantly lower TTR protein levels at the 28th week ( P = 0.003) and 30th week ( P = 0.004) were found in the T2DM groups compared with the control group.

Total burn incidence showed a trend to increase with increasing grade level (Cochran-Armitage trend test, P = 0.003), but this trend only appeared in females.

Univariate analysis revealed that female gender, young age, and no smoking history showed a trend to association with better OS, and good performance status (21.6 months vs. 16.9 months, p=0.003), less advanced stage (19.1 months vs. 13.2 months, p=0.041), and receiving second-line treatment (20.5 months vs. 15.1 months, p=0.049) were significantly associated with better OS.

Regarding therapy modalities, PPV led to significantly improved visual outcomes (χ 2 = 87.15, P < 0.0001), and the pre-therapy VA displayed an important role in improving vision, especially the patient’s VA ≦logMAR 2.3 showed a trend of statistically significant improvement (χ 2 = 9.00, P = 0.003).

HOX B13 showed a trend of statistical association with sex and age, and a strong direct statistical association with lymph nodes metastasis (p value = 0.003).

392.2 ± 16.3 g, p < 0.001); the pre-EMPA + DOX group (group V) showed a trend towards weight loss over the longer 28-day period (422.4 ± 13.7 g vs. 395.7 ± 15.6 g, p = 0.003).

The McNemar test showed a trend toward practice category improving from baseline to the 4-weeks follow-up assessment ( P = 0.003).

Cognitively normal and impaired patients showed a trend towards an increased metabolic connectivity between the AGr and the sLOCr compared to controls (PD‐NC: z = −3.02, p = .003; PD‐MCI: z = −1.57, p = .116); patients with MCI additionally between the PC and sLOCr ( z = −2.02, p value = .043; Figure 4a,b ).

T 2m was used to assess the extent of muscle oedema 5 and showed a trend to decrease over time at thigh and calf level over the iMOP ( table 1 , online supplemental figure 3 , Bonferroni-corrected p>0.003).

Five miRNAs, including miR-31 ( P < 0.001), miR-191 ( P = 0.006), miR-155 ( P < 0.002), miR-126 ( P = 0.023) and miR-141 ( P = 0.056), were markedly higher or showed a trend of being higher in stage IV CRC, while miR-519b-3p had lower levels ( P = 0.003) in stage IV CRC.